On Wednesday, Castle Biosciences got an upgrade to its Relative Strength (RS) Rating, from 88 to 92.
This exclusive rating from Investor's Business Daily measures share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an RS Rating north of 80 as they begin their largest price moves.
How To Use Stock Charts To Stay Profitable And Protected
Castle Biosciences is building a double bottom with a 32.60 entry. See if the stock can break out in heavy trading.
Castle Biosciences showed 0% EPS growth in the latest quarterly report, while sales growth came in at 40%.
Castle Biosciences earns the No. 1 rank among its peers in the Medical-Services industry group. Hims & Hers Health and NeoGenomics are also among the group's highest-rated stocks.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
